660-49-1

Basic information

• Product Name: 3-FLUORO-5-IODOANILINE
• Synonyms: 3-FLUORO-5-IODOANILINE;3-FLUORO-5-IODO-PHENYLAMINE;5-FLUORO-3-IODOANILINE
• CAS NO: 660-49-1
• Molecular Formula: C₆H₅FIN
• Molecular Weight: 237.01
• Mol File: 660-49-1.mol

Chemical Properties

• Boiling Point: 279.5 °C at 760 mmHg
• Flash Point: 122.8 °C
• Appearance: /
• Density: 2.008 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.656
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.62±0.10(Predicted)
• Sensitive: Light Sensitive
• CAS DataBase Reference: 3-FLUORO-5-IODOANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-FLUORO-5-IODOANILINE(660-49-1)
• EPA Substance Registry System: 3-FLUORO-5-IODOANILINE(660-49-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 660-49-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-5-iodoaniline is used as a key intermediate in the synthesis of various pharmaceuticals for its unique structural properties that can contribute to the development of new drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Fluoro-5-iodoaniline is utilized as a building block in the creation of compounds that can be used in pesticides or other agricultural chemicals, potentially enhancing crop protection and yield.
Used in Dye Industry:
3-Fluoro-5-iodoaniline is employed as a precursor in the production of dyes, where its molecular structure contributes to the color and properties of the final dye products.
Used in Organic Compounds Production:
As an intermediate, 3-Fluoro-5-iodoaniline is crucial in the synthesis of a range of organic compounds, facilitating the creation of new materials with diverse applications across various industries.
Used in Research Laboratories:
In research settings, 3-Fluoro-5-iodoaniline is used for experimental purposes, allowing scientists to explore its chemical properties and potential applications in new areas of study.

InChI:InChI=1/C6H5FIN/c7-4-1-5(8)3-6(9)2-4/h1-3H,9H2

Upstream product

• 3819-88-3 1-fluoro-3-iodo-5-nitrobenzene 
• 99-65-0 meta-dinitrobenzene 

Downstream Products

• 852807-42-2 1-(3-fluoro-5-iodophenyl)piperazine 
• 1369808-80-9 3-fluoro-5-iodo-N,N-dimethylaniline 
• 710348-26-8 N-(3-fluoro-5-iodophenyl)methanesulfonamide 
• 1027953-88-3 3-[4-(3-fluoro-5-iodophenyl)piperazin-1-yl]-1-[5-methyl-1-(pyrimidin-2-yl)-1H-pyrazol-4-yl]propan-1-one 

Relevant articles and documents

PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF

Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.

Design, synthesis and discovery of picomolar selective α4β2 nicotinic acetylcholine receptor ligands

Developing novel and selective compounds that desensitize α4β2 nicotinic acetylcholine receptors (nAChRs) could provide new effective treatments for nicotine addiction, as well as other disorders. Here we report a new class of nAChR ligands that display high selectivity and picomolar binding affinity for α4β2 nicotinic receptors. The novel compounds have Ki values in the range of 0.031-0.26 nM and properties that should make them good candidates as drugs acting in the CNS. The selected lead compound 1 (VMY-2-95) binds with high affinity and potently desensitizes α4β2 nAChRs. At a dose of 3 mg/kg, compound 1 significantly reduced rat nicotine self-administration. The overall results support further characterizations of compound 1 and its analogues in preclinical models of nicotine addiction and perhaps other disorders involving nAChRs.

Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. III. Synthesis and antitumor activity of 3-phenylpiperazinyl-1-trans-propenes

A series of novel 3-[4-phenyl-1-piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)- 4-pyrazolyl]-1-trans-propenes and related compounds were synthesized and evaluated by their cytotoxic activity against several tumor cell lines in vitro and in vivo antitumor acti

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.

Substituted 5-benzyl-2,4-diaminopyrimidines

The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1is C2-C3 alkyl an R2is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2and R3can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations. The products have antibiotic properties and are useful for combating or preventing infectious diseases.